Libido and arousal — both genders
PT-141 — central-acting desire support, distinct from PDE5.
- HIPAA-Compliant
- US-Licensed Physicians
- PCAB-Accredited Compounding
- Available in 46 States
- Telehealth-Compliant
About this protocol
A central-acting libido protocol built around PT-141 (Bremelanotide) — FDA-approved for hypoactive sexual desire disorder in women and studied off-label for men. Unlike PDE5 inhibitors that act on vascular tone, PT-141 activates melanocortin receptors in the brain — the desire pathway, not the performance pathway. Kisspeptin can be layered as a clinician-directed adjunct when HPG-axis support is indicated.
Who it's for: Men and women noticing libido or desire decline — particularly when the motivational, central component feels as relevant as physical performance.
What's in this protocol
SPARK is built around a single compound:
PT-141
Bremelanotide
FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women; studied off-label for men. Activates melanocortin receptors MC3R and MC4R in the central nervous system — a desire-pathway mechanism distinct from PDE5 inhibitors.
Used for
What members are working toward
The following reflects areas of interest commonly reported by members and studied in the clinical literature. Results depend on individual health status, labs, and physician-directed care. Nothing below constitutes a treatment claim.
Centrally-acting desire
PT-141 works through brain pathways involved in sexual motivation — distinct from the vascular mechanism of PDE5 inhibitors.
Both genders
FDA-approved for women and used off-label for men — the single protocol addressing central desire for both.
Clinical adjunct option
When the HPG-axis picture warrants it, the physician can layer Kisspeptin as a clinician-directed adjunct.
Relevant labs markers
SPARK is prescribed and monitored against labs. The Halftime Baseline panel ($249, separate onboarding deliverable) covers the relevant markers below.
How to subscribe
Available at every tier
- Foundation $199/mo — pick SPARK as your 1 protocol
- Optimizer $349/mo — pair SPARK with 1 other protocol
- Elite $549/mo — stack SPARK with 2 other protocols
The Halftime Baseline lab panel ($249) is a separate onboarding deliverable, available at any tier.
Join the waitlistLaunching July 1, 2026
All prescriptions require physician evaluation. Compounded medications are not FDA-approved. Individual results vary. This is not medical advice.